Igos

Arsenic trioxide, the active ingredient in Igos, is an antineoplastic agent presented as a sterile solution for intravenous use. It is employed in the treatment of acute promyelocytic leukemia, targeting malignant promyelocytes in adult patients. GNH USA supplies Igos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Igos (arsenic trioxide) is used within the acute promyelocytic leukemia (APL) therapeutic pathway to achieve disease control. - Acute promyelocytic leukemia (newly diagnosed): induces remission by promoting differentiation of leukemic cells. - Acute promyelocytic leukemia (relapsed or refractory): provides disease control when standard therapy has failed. - High‑risk acute promyelocytic leukemia: contributes to differentiation therapy as part of combination regimens.

Arsenic trioxide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during therapy. - Fever: transient elevations in body temperature. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Mild QT interval prolongation: detectable on ECG monitoring.

Serious or Rare Side Effects: - Differentiation syndrome: potentially life‑threatening inflammatory response. - Severe QT prolongation: risk of torsades de pointes arrhythmia. - Hepatic toxicity: elevated liver enzymes or hepatic dysfunction. - Renal failure: impaired kidney function requiring monitoring. - Severe infection: opportunistic infections due to immunosuppression. - Leukocytosis: rapid rise in white blood cell count.

When using Igos, clinicians should observe specific safety measures to minimize risk. - Cardiac monitoring: perform baseline and periodic ECGs to detect QT prolongation. - Electrolyte management: correct potassium and magnesium deficits before infusion. - Hepatic function: assess liver enzymes and adjust therapy if significant impairment exists. - Pregnancy considerations: avoid use in pregnant women unless benefits outweigh potential risks. - Differentiation syndrome vigilance: monitor for fever, weight gain, respiratory distress, and intervene promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Arsenic trioxide can interact with other medicines, altering safety or efficacy.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of dangerous arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise arsenic levels. - Azole antifungals: potentiate toxicity through metabolic inhibition.

Moderate Interactions (Monitor Closely): - All‑trans retinoic acid (ATRA): heightened risk of differentiation syndrome; monitor closely. - Diuretics: may exacerbate electrolyte disturbances; check serum potassium and magnesium. - Electrolyte supplements: adjust dosing to avoid over‑correction of potassium/magnesium.